The results are likely to be more relevant to patients in sub-Saharan Africa than to those in high-resource settings, the authors say.

Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – ...

FRIENDSWOOD, Texas, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its ...

Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the launch of AdvanceAD-Tx™, a gene expression profile (GEP) test ...

Sac-TMT will compete with two other TROP-2 targeted ADCs already approved: Gilead’s Trodelvy and AstraZeneca and Daiichi ...

Determining the type of diabetes a patient has at diagnosis can be challenging, and health care professionals should focus on each patient’s clinical condition when determining initial treatment, ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced ...

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on ...

The second-line use of CDK4/6 inhibitors in advanced breast cancer saves substantial costs while maintaining health outcomes ...

Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in ...